ClinicalTrials.gg
CompletedNCT02549469Updated Sep 15, 2015

Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily

A Phase 1 interventional study of Naproxen Sodium ER (BAY117031), 20% HPMC and Naproxen Sodium ER (BAY117031), 30% HPMC in Pain, sponsored by Bayer. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-15.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.

Enrollment
21st of 25
32 · median 100
Started
2007
the only one that year
Phase 1
5 of 25
none open now
Registered
11th of 25
by date
Lead sponsor
9 of 25
Bayer

Among the 25 studies testing naproxen in Pain, this one is the 21st largest by enrollment, is the only one that started in 2007, is one of 5 in phase 1, and was the 11th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing naproxen in Pain, or all of them as a file.
02

Study summary

Bioequivalence trial in healthy adult subjects to determine the bioavailability of 3 different sustained release formulations of naproxen 660 mg relative to the established commercial Aleve 220 mg tablet.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy ambulatory male and female subjects 18 to 55 years of age, inclusive
  • (BMI) of approximately 18.0 to 30.0 kg/m2, and a total body weight >50 kg (110 lbs)
  • Results of screening and clinical laboratory tests are within normal limits or considered not by the Principal Investigator or Sponsor
  • Female subjects of must be using a medically acceptable form of for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, intramuscular injection or double-barrier and have a negative pregnancy test at Screening and on Day 0 of each treatment period. Female subjects of nonchildbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy.
  • Provide a personally signed and dated prior to inclusion in the trial indicating that the subject has been informed of all pertinent aspects of the trial.

Exclusion criteria

Exclusion Criteria:

  • History of to aspirin (ASA), naproxen sodium, or acetaminophen, and similar pharmacological agents or components of the products
  • History of gastrointestinal bleeding or perforation, including bleeding related to previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding).
  • Have taken ASA, ASA-containing products, acetaminophen (acetyl-para-amino-phenol or APAP) or any other NSAID (OTC or prescription) 7 days prior to dosing or during the treatment period, other than study treatment
  • Loss of blood in excess of 500 mL within 56 days of the first dose of trial treatment (e.g., donation, plasmapheresis, or injury)
  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
  • Positive alcohol or drug screen at Screening or on Day 0 of Treatment Periods 1 or 2
  • Females who are pregnant or lactating
  • Smokers or currently consuming any type of tobacco product(s) including any smoking cessation nicotine-containing product (eg, nicotine patch, nicotine gum).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Naproxen sodium extended release 660 mg, 20% HPMC

    Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve (Naproxen sodium) 220 mg tablet

    Drug: Naproxen Sodium ER (BAY117031), 20% HPMC

  • Experimental
    Naproxen sodium extended release 660 mg, 30% HPMC

    Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet

    Drug: Naproxen Sodium ER (BAY117031), 30% HPMC

  • Experimental
    Naproxen sodium extended release 660 mg, 40% HPMC

    Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet

    Drug: Naproxen Sodium ER (BAY117031), 40% HPMC

  • Active comparator
    Naproxen sodium 220 mg

    Bioequivalence in healthy adult subjects in a fasted state

    Drug: Aleve (Naproxen Sodium, BAY117031)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (maximum plasma concentration) for naproxen sodium

    Time frame: Days 0, 1, 2, and 3

  2. AUC0-24 (partial area under the curve ) for naproxen sodium

    Time frame: Days 0, 1, 2, and 3

  3. AUC0-t (areas under the curve ) for naproxen sodium

    Time frame: Days 0, 1, 2, and 3

  4. AUC0-∞ (area under the curve) for naproxen sodium

    Time frame: Days 0, 1, 2, and 3

  5. Tmax (The first time point where Cmax is reached) for naproxen sodium

    Time frame: Days 0, 1, 2, and 3

  6. AUC0-8 (partial area under the curve) for naproxen sodium

    Time frame: Days 0, 1, 2, and 3

  7. AUC8-16 (partial area under the curve ) for naproxen sodium

    Time frame: Days 0, 1, 2, and 3

  8. AUC16-24 (partial area under the curve) for naproxen sodium

    Time frame: Days 0, 1, 2, and 3

  9. λz (terminal elimination rate constant)

    Time frame: Days 0, 1, 2, and 3

  10. t1/2 (terminal half life)

    Time frame: Days 0, 1, 2, and 3

Secondary outcomes

  1. Adverse events (AEs) collection

    Time frame: up to 50 days

  2. Serious adverse events (SAEs) collection

    Time frame: up to 50 days

  3. Vital signs: sitting blood pressure

    Time frame: up to 50 days

  4. Vital signs: repiratory rate

    Time frame: up to 50 days

  5. Vital signs : pulse rate

    Time frame: up to 50 days

  6. Clinical Laboratory data

    Blood and urine samples were collected according to standard medical guidelines at the Screening Visit. In addition, hematology and chemistry were obtained at the end of the study (EOS).

    Time frame: up to 50 days

  7. Physical examination findings

    Brief physical examination, including height, weight and BMI, was performed at the Screening Visit and at EOS

    Time frame: up to 50 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of May 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2015
First posted
Sep 15, 2015
Start
Mar 2007
Primary completionActual
May 2007
CompletionActual
May 2007
Last update
Sep 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02549469
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 15, 2015
Start date
Mar 2007
Primary completion
May 2007
Completion
May 2007
Last update
Sep 15, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion